## J Kevin Baird

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3434572/publications.pdf

Version: 2024-02-01

		23500	25716
159	12,893	58	108
papers	citations	h-index	g-index
169	169	169	8323
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Methaemoglobinaemia and the radical curative efficacy of 8â€aminoquinoline antimalarials. British Journal of Clinical Pharmacology, 2022, 88, 2657-2664.	1.1	5
2	African Plasmodium vivax malaria improbably rare or benign. Trends in Parasitology, 2022, 38, 683-696.	1.5	13
3	Evaluating Saliva Sampling with Reverse Transcription Loop-mediated Isothermal Amplification to Improve Access to SARS-CoV-2 Diagnosis in Low-Resource Settings. American Journal of Tropical Medicine and Hygiene, 2022, , .	0.6	O
4	Efficacy and safety of tafenoquine for malaria chemoprophylaxis (1998–2020): A systematic review and meta-analysis. Travel Medicine and Infectious Disease, 2021, 39, 101908.	1.5	10
5	Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. The Lancet Regional Health - Western Pacific, 2021, 9, 100108.	1.3	75
6	Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study. Malaria Journal, 2021, 20, 177.	0.8	10
7	Single loading-dose tafenoquine for malaria chemoprophylaxis during brief travel?. Journal of Travel Medicine, 2021, 28, .	1.4	2
8	Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria. PLoS Neglected Tropical Diseases, 2021, 15, e0009610.	1.3	7
9	Basic Research of Plasmodium vivax Biology Enabling Its Management as a Clinical and Public Health Problem. Frontiers in Cellular and Infection Microbiology, 2021, 11, 696598.	1.8	5
10	Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria. PLoS Neglected Tropical Diseases, 2021, 15, e0009690.	1.3	5
11	The global burden of Plasmodium vivax malaria is obscure and insidious. PLoS Medicine, 2021, 18, e1003799.	3.9	37
12	Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: A prospective open-label efficacy trial. Travel Medicine and Infectious Disease, 2020, 36, 101499.	1.5	19
13	Male swarming aggregation pheromones increase female attraction and mating success among multiple African malaria vector mosquito species. Nature Ecology and Evolution, 2020, 4, 1395-1401.	3.4	40
14	Chloroquine Potentiates Primaquine Activity against Active and Latent Hepatic Plasmodia <i>Ex Vivo</i> : Potentials and Pitfalls. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	7
15	Towards harmonization of microscopy methods for malaria clinical research studies. Malaria Journal, 2020, 19, 324.	0.8	13
16	Efficacy of a Spatial Repellent for Control of Malaria in Indonesia: A Cluster-Randomized Controlled Trial. American Journal of Tropical Medicine and Hygiene, 2020, 103, 344-358.	0.6	53
17	Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report. BMC Infectious Diseases, 2019, 19, 704.	1.3	20
18	The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2019, 17, 151.	2.3	34

#	Article	IF	Citations
19	8-Aminoquinoline Therapy for Latent Malaria. Clinical Microbiology Reviews, 2019, 32, .	5.7	77
20	Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet, The, 2019, 394, 929-938.	6.3	106
21	Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency. Journal of Infectious Diseases, 2019, 220, 1750-1760.	1.9	8
22	The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	3.9	27
23	Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study. Lancet, The, 2019, 394, 332-343.	6.3	276
24	"Lively―invasive Plasmodium vivax causes severe and complicated malaria. Travel Medicine and Infectious Disease, 2019, 30, 7-8.	1.5	5
25	Growing evidence of Plasmodium vivax across malaria-endemic Africa. PLoS Neglected Tropical Diseases, 2019, 13, e0007140.	1.3	135
26	Essential guidance on malaria elimination in its history. Journal of Vector Borne Diseases, 2019, 56, 11.	0.1	3
27	Negligible Impact of Mass Screening and Treatment on Mesoendemic Malaria Transmission at West Timor in Eastern Indonesia: A Cluster-Randomized Trial. Clinical Infectious Diseases, 2018, 67, 1364-1372.	2.9	30
28	Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent <i>Plasmodium vivax</i> Malaria. JAMA Network Open, 2018, 1, e181449.	2.8	77
29	Tafenoquine for travelers' malaria: evidence, rationale and recommendations. Journal of Travel Medicine, 2018, 25, .	1.4	42
30	The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1025-1034.	4.6	85
31	Accurate light microscopic diagnosis of Southâ€East Asian ovalocytosis. International Journal of Laboratory Hematology, 2018, 40, 655-662.	0.7	6
32	Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms. Malaria Journal, 2018, 17, 42.	0.8	60
33	Malaria Elimination: Time to Target All Species. American Journal of Tropical Medicine and Hygiene, 2018, 99, 17-23.	0.6	62
34	Telling the human story of Asia's invisible malaria burden. Lancet, The, 2017, 389, 781-782.	6.3	5
35	Rational malaria chemoprophylaxis – The position of primaquine. Travel Medicine and Infectious Disease, 2017, 17, 3-4.	1.5	4
36	Malaria control by commodities without practical malariology. BMC Public Health, 2017, 17, 590.	1.2	11

#	Article	IF	Citations
37	Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malaria Journal, 2017, 16, 141.	0.8	52
38	Management of Plasmodium vivax risk and illness in travelers. Tropical Diseases, Travel Medicine and Vaccines, 2017, 3, 7.	0.9	14
39	Asia-Pacific malaria is singular, pervasive, diverse and invisible. International Journal for Parasitology, 2017, 47, 371-377.	1.3	25
40	Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles. PLoS Neglected Tropical Diseases, 2017, 11, e0005516.	1.3	24
41	The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies. PLoS Medicine, 2016, 13, e1001984.	3.9	49
42	Assessment of Point-of-Care Diagnostics for G6PD Deficiency in Malaria Endemic Rural Eastern Indonesia. PLoS Neglected Tropical Diseases, 2016, 10, e0004457.	1.3	35
43	Diagnosis and Treatment of <i>Plasmodium vivax</i> Malaria. American Journal of Tropical Medicine and Hygiene, 2016, 95, 35-51.	0.6	65
44	Global Epidemiology of <i>Plasmodium vivax</i> . American Journal of Tropical Medicine and Hygiene, 2016, 95, 15-34.	0.6	287
45	Key Knowledge Gaps for <i>Plasmodium vivax</i> Control and Elimination. American Journal of Tropical Medicine and Hygiene, 2016, 95, 62-71.	0.6	39
46	Epidemiology of <i>Plasmodium vivax</i> in Indonesia. American Journal of Tropical Medicine and Hygiene, 2016, 95, 121-132.	0.6	18
47	Global database of matched Plasmodium falciparum and P. vivax incidence and prevalence records from 1985–2013. Scientific Data, 2015, 2, 150012.	2.4	22
48	Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Medicine, 2015, 13, 294.	2.3	47
49	Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency. BMC Medicine, 2015, 13, 296.	2.3	35
50	The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malaria Journal, 2015, 14, 377.	0.8	51
51	Defining the relationship between Plasmodium vivax parasite rate and clinical disease. Malaria Journal, 2015, 14, 191.	0.8	12
52	Optimum population-level use of artemisinin combination therapies: a modelling study. The Lancet Global Health, 2015, 3, e758-e766.	2.9	62
53	Global extent of chloroquine-resistant Plasmodium vivax – Authors' reply. Lancet Infectious Diseases, The, 2015, 15, 630-631.	4.6	2
54	Still defining optimal primaquine therapy against relapse after 63 years of continuous use. Travel Medicine and Infectious Disease, 2015, 13, 215-216.	1.5	2

#	Article	IF	CITATIONS
55	G6PD Deficiency at Sumba in Eastern Indonesia Is Prevalent, Diverse and Severe: Implications for Primaquine Therapy against Relapsing Vivax Malaria. PLoS Neglected Tropical Diseases, 2015, 9, e0003602.	1.3	30
56	Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Translational Research, 2015, 165, 677-688.	2.2	36
57	Malaria eradication and elimination: views on how to translate a vision into reality. BMC Medicine, 2015, 13, 167.	2.3	101
58	Therapeutic Responses of Plasmodium vivax Malaria to Chloroquine and Primaquine Treatment in Northeastern Myanmar. Antimicrobial Agents and Chemotherapy, 2015, 59, 1230-1235.	1.4	48
59	Distance to <i>Anopheles sundaicus</i> li>larval habitats dominant among risk factors for parasitemia in meso-endemic Southwest Sumba, Indonesia. Pathogens and Global Health, 2014, 108, 369-380.	1.0	11
60	Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2014, 14, 982-991.	4.6	300
61	The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malaria Journal, 2014, 13, 488.	0.8	51
62	Severe Morbidity and Mortality Risk From Malaria in the United States, 1985–2011. Open Forum Infectious Diseases, 2014, 1, ofu034.	0.4	37
63	Defining the Geographical Range of the Plasmodium knowlesi Reservoir. PLoS Neglected Tropical Diseases, 2014, 8, e2780.	1.3	84
64	Impact of a Spatial Repellent on Malaria Incidence in Two Villages in Sumba, Indonesia. American Journal of Tropical Medicine and Hygiene, 2014, 91, 1079-1087.	0.6	76
65	Geographical variation in Plasmodium vivax relapse. Malaria Journal, 2014, 13, 144.	0.8	223
66	Suppressive chemoprophylaxis invites avoidable risk of serious illness caused byÂPlasmodium vivax malaria. Travel Medicine and Infectious Disease, 2013, 11, 60-65.	1.5	15
67	Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malaria Journal, 2013, 12, 418.	0.8	135
68	The Distribution and Bionomics of Anopheles Malaria Vector Mosquitoes in Indonesia. Advances in Parasitology, 2013, 83, 173-266.	1.4	60
69	G6PD Deficiency. Advances in Parasitology, 2013, 81, 133-201.	1.4	181
70	Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria. Clinical Microbiology Reviews, 2013, 26, 36-57.	5.7	312
71	Malaria caused by $\langle i \rangle$ Plasmodium $\langle i \rangle$ : recurrent, difficult to treat, disabling, and threatening to life $\hat{a} \in \mathcal{C}$ averting the infectious bite preempts these hazards. Pathogens and Global Health, 2013, 107, 475-479.	1.0	38
72	Randomized, Open-Label Trial of Primaquine against Vivax Malaria Relapse in Indonesia. Antimicrobial Agents and Chemotherapy, 2013, 57, 1128-1135.	1.4	71

#	Article	IF	Citations
73	Purnomo Projodipuro (April 11, 1934–May 10, 2013). American Journal of Tropical Medicine and Hygiene, 2013, 89, 202-204.	0.6	О
74	Tropical Health and Sustainability. , 2013, , 309-351.		1
75	A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010. PLoS Neglected Tropical Diseases, 2012, 6, e1814.	1.3	448
76	Preface. Advances in Parasitology, 2012, 80, ix-x.	1.4	0
77	G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based Map. PLoS Medicine, 2012, 9, e1001339.	3.9	404
78	Serious and Fatal Illness Associated with Falciparum and Vivax Malaria among Patients Admitted to Hospital at West Sumba in Eastern Indonesia. American Journal of Tropical Medicine and Hygiene, 2012, 87, 41-49.	0.6	30
79	Diagnosis and Treatment of Plasmodium vivax Malaria. Advances in Parasitology, 2012, 80, 203-270.	1.4	62
80	Primaquine toxicity forestalls effective therapeutic management of the endemic malarias. International Journal for Parasitology, 2012, 42, 1049-1054.	1.3	24
81	Human ex vivo studies on asexual Plasmodium vivax: The best way forward. International Journal for Parasitology, 2012, 42, 1063-1070.	1.3	40
82	Chemotherapeutics challenges in developing effective treatments for the endemic malarias. International Journal for Parasitology: Drugs and Drug Resistance, 2012, 2, 256-261.	1.4	3
83	The Global Public Health Significance of Plasmodium vivax. Advances in Parasitology, 2012, 80, 1-111.	1.4	105
84	Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malaria Journal, 2012, 11, 280.	0.8	155
85	Plasmodium vivax Malaria Endemicity in Indonesia in 2010. PLoS ONE, 2012, 7, e37325.	1.1	35
86	Elimination Therapy for the Endemic Malarias. Current Infectious Disease Reports, 2012, 14, 227-237.	1.3	8
87	Malaria Distribution, Prevalence, Drug Resistance and Control in Indonesia. Advances in Parasitology, 2011, 74, 41-175.	1.4	104
88	Phenotyping clinical resistance to chloroquine in Plasmodium vivax in northeastern Papua, Indonesia. International Journal for Parasitology: Drugs and Drug Resistance, 2011, 1, 28-32.	1.4	9
89	Consideration of ethics in primaquine therapy against malaria transmission. Trends in Parasitology, 2011, 27, 11-16.	1.5	61
90	Review: Improving the Therapeutic Index of 8-Aminoquinolines by the Use of Drug Combinations: Review of the Literature and Proposal for Future Investigations. American Journal of Tropical Medicine and Hygiene, 2011, 85, 1010-1014.	0.6	29

#	Article	IF	Citations
91	Resistance to Chloroquine Unhinges Vivax Malaria Therapeutics. Antimicrobial Agents and Chemotherapy, 2011, 55, 1827-1830.	1.4	55
92	Radical Cure: The Case for Anti-Relapse Therapy Against All Malarias. Clinical Infectious Diseases, 2011, 52, 621-623.	2.9	12
93	Plasmodium falciparum Malaria Endemicity in Indonesia in 2010. PLoS ONE, 2011, 6, e21315.	1.1	51
94	Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends in Parasitology, 2010, 26, 145-151.	1.5	222
95	The International Limits and Population at Risk of Plasmodium vivax Transmission in 2009. PLoS Neglected Tropical Diseases, 2010, 4, e774.	1.3	405
96	Clinical Course of Avian Influenza A(H5N1) in Patients at the Persahabatan Hospital, Jakarta, Indonesia, 2005–2008. Chest, 2010, 138, 665-673.	0.4	24
97	Eliminating malariaâ€"all of them. Lancet, The, 2010, 376, 1883-1885.	6.3	47
98	Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malaria Journal, 2010, 9, 52.	0.8	28
99	Resistance to Therapies for Infection by <i>Plasmodium vivax</i> . Clinical Microbiology Reviews, 2009, 22, 508-534.	5.7	236
100	Acquired Immunity to Malaria. Clinical Microbiology Reviews, 2009, 22, 13-36.	5.7	981
101	Histopathology of Fatal Respiratory Distress Caused by Plasmodium vivax Malaria. American Journal of Tropical Medicine and Hygiene, 2009, 81, 758-762.	0.6	82
102	Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infectious Diseases, The, 2009, 9, 555-566.	4.6	565
103	Malaria zoonoses. Travel Medicine and Infectious Disease, 2009, 7, 269-277.	1.5	55
104	Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. American Journal of Tropical Medicine and Hygiene, 2009, 81, 338-42.	0.6	19
105	Discordant Patterns of Genetic Variation at Two Chloroquine Resistance Loci in Worldwide Populations of the Malaria Parasite <i>Plasmodium falciparum</i> Chemotherapy, 2008, 52, 2212-2222.	1.4	67
106	Acquisition of Invasionâ€Inhibitory Antibodies Specific for the 19â€kDa Fragment of Merozoite Surface Protein 1 in a Transmigrant Population Requires Multiple Infections. Journal of Infectious Diseases, 2008, 198, 1212-1218.	1.9	11
107	Real-World Therapies and the Problem of Vivax Malaria. New England Journal of Medicine, 2008, 359, 2601-2603.	13.9	31
108	High-dose Primaquine Regimens against Relapse of Plasmodium vivax Malaria. American Journal of Tropical Medicine and Hygiene, 2008, 78, 736-740.	0.6	76

#	Article	IF	CITATIONS
109	High-dose primaquine regimens against relapse of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene, 2008, 78, 736-40.	0.6	39
110	Neglect of Plasmodium vivax malaria. Trends in Parasitology, 2007, 23, 533-539.	1.5	224
111	Prevention and treatment of vivax malaria. Current Infectious Disease Reports, 2007, 9, 39-46.	1.3	41
112	Demographic Risk Factors for Severe and Fatal Vivax and Falciparum Malaria Among Hospital Admissions in Northeastern Indonesian Papua. American Journal of Tropical Medicine and Hygiene, 2007, 77, 984-991.	0.6	165
113	Acquired immunity in a holoendemic setting of Plasmodium falciparum and p. Vivax malaria. American Journal of Tropical Medicine and Hygiene, 2007, 76, 995-6.	0.6	4
114	Mefloquine treatment for uncomplicated falciparum malaria in young children 6-24 months of age in northern Ghana. American Journal of Tropical Medicine and Hygiene, 2007, 76, 224-31.	0.6	3
115	Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. American Journal of Tropical Medicine and Hygiene, 2007, 77, 984-91.	0.6	101
116	Mefloquine Is Highly Efficacious against Chloroquine-Resistant Plasmodium vivax Malaria and Plasmodium falciparum Malaria in Papua, Indonesia. Clinical Infectious Diseases, 2006, 42, 1067-1072.	2.9	66
117	PRIMAQUINE: REPORT FROM CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS I. American Journal of Tropical Medicine and Hygiene, 2006, 75, 402-415.	0.6	283
118	Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. American Journal of Tropical Medicine and Hygiene, 2006, 75, 402-15.	0.6	139
119	Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Experimental Parasitology, 2005, 109, 256-259.	0.5	72
120	Novel Plasmodium vivax dhfr Alleles from the Indonesian Archipelago and Papua New Guinea: Association with Pyrimethamine Resistance Determined by a Saccharomyces cerevisiae Expression System. Antimicrobial Agents and Chemotherapy, 2005, 49, 733-740.	1.4	60
121	Effectiveness of Antimalarial Drugs. New England Journal of Medicine, 2005, 352, 1565-1577.	13.9	313
122	Dihydrofolate Reductase Mutations in Plasmodium vivax from Indonesia and Therapeutic Response to Sulfadoxine plus Pyrimethamine. Journal of Infectious Diseases, 2004, 189, 744-750.	1.9	95
123	Chloroquine Resistance in Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 2004, 48, 4075-4083.	1.4	300
124	Primaquine Therapy for Malaria. Clinical Infectious Diseases, 2004, 39, 1336-1345.	2.9	369
125	The Contextual Determinants of Malaria. American Journal of Tropical Medicine and Hygiene, 2004, 70, 458-458.	0.6	0
126	Can primaquine therapy for vivax malaria be improved?. Trends in Parasitology, 2003, 19, 115-120.	1.5	148

#	Article	IF	Citations
127	A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Doseâ€Ranging Trial of Tafenoquine for Weekly Prophylaxis againstPlasmodium falciparum. Clinical Infectious Diseases, 2003, 36, 541-549.	2.9	79
128	Primaquine for Prevention of Malaria in Travelers. Clinical Infectious Diseases, 2003, 37, 1659-1667.	2.9	109
129	VERY HIGH RISK OF THERAPEUTIC FAILURE WITH CHLOROQUINE FOR UNCOMPLICATED PLASMODIUM FALCIPARUM AND P. VIVAX MALARIA IN INDONESIAN PAPUA. American Journal of Tropical Medicine and Hygiene, 2003, 68, 416-420.	0.6	107
130	Identification of a polymorphic Plasmodium vivax microsatellite marker. American Journal of Tropical Medicine and Hygiene, 2003, 69, 377-9.	0.6	19
131	Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. American Journal of Tropical Medicine and Hygiene, 2003, 68, 416-20.	0.6	63
132	The American Society of Tropical Medicine and Hygiene should keep its name. American Journal of Tropical Medicine and Hygiene, 2003, 69, 234-5.	0.6	0
133	Atovaquone/Proguanil Therapy forPlasmodium falciparumandPlasmodium vivaxMalaria in Indonesians Who Lack Clinical Immunity. Clinical Infectious Diseases, 2002, 35, e92-e95.	2.9	33
134	Randomized, Placeboâ€Controlled Trial of Atovaquone/Proguanil for the Prevention ofPlasmodium falciparumorPlasmodium vivaxMalaria among Migrants to Papua, Indonesia. Clinical Infectious Diseases, 2002, 35, 825-833.	2.9	82
135	Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet, The, 2002, 360, 58-60.	6.3	96
136	Seasonal malaria attack rates in infants and young children in northern Ghana American Journal of Tropical Medicine and Hygiene, 2002, 66, 280-286.	0.6	70
137	A biologic basis for integrated malaria control American Journal of Tropical Medicine and Hygiene, 2002, 67, 571-577.	0.6	30
138	Multistage Multiantigen Heterologous Prime Boost Vaccine forPlasmodium knowlesi Malaria Provides Partial Protection in Rhesus Macaques. Infection and Immunity, 2001, 69, 5565-5572.	1.0	80
139	Resurgent Malaria at the Millennium. Drugs, 2000, 59, 719-743.	4.9	76
140	Malaria in a Nonimmune Population after Extended Chloroquine or Primaquine Prophylaxis. American Journal of Tropical Medicine and Hygiene, 1997, 56, 137-140.	0.6	21
141	Survey of in Vivo Sensitivity to Chloroquine by Plasmodium falciparum and P. vivax in Lombok, Indonesia. American Journal of Tropical Medicine and Hygiene, 1997, 56, 241-244.	0.6	29
142	Whole Blood Chloroquine Concentrations with Plasmodium vivax Infection in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene, 1997, 56, 618-620.	0.6	19
143	Diagnosis of Resistance to Chloroquine by Plasmodium vivax: Timing of Recurrence and Whole Blood Chloroquine Levels. American Journal of Tropical Medicine and Hygiene, 1997, 56, 621-626.	0.6	153
144	Progress in prevention and treatment of malaria. Current Opinion in Infectious Diseases, 1996, 9, 319-329.	1.3	3

#	Article	IF	Citations
145	A Focus of Endemic Malaria in Central Java. American Journal of Tropical Medicine and Hygiene, 1996, 54, 98-104.	0.6	26
146	Treatment of Chloroquine-Resistant Plasmodium vivax with Chloroquine and Primaquine or Halofantrine. Journal of Infectious Diseases, 1995, 171, 1678-1682.	1.9	106
147	Primaquine for Prophylaxis against Malaria among Nonimmune Transmigrants in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene, 1995, 52, 479-484.	0.6	59
148	Age-Specific Prevalence of Plasmodium falciparum Among Six Populations with Limited Histories of Exposure to Endemic Malaria. American Journal of Tropical Medicine and Hygiene, 1993, 49, 707-719.	0.6	68
149	Evidence for Specific Suppression of Gametocytemia by Plasmodium Falciparum in Residents of Hyperendemic Irian Jaya. American Journal of Tropical Medicine and Hygiene, 1991, 44, 183-190.	0.6	40
150	Resistance to Chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene, 1991, 44, 547-552.	0.6	197
151	Resistance to Antimalarials by Plasmodium falciparum in Arso Pir, Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene, 1991, 44, 640-644.	0.6	35
152	Age-Dependent Acquired Protection against Plasmodium Falciparum in People Having Two Years Exposure to Hyperendemic Malaria. American Journal of Tropical Medicine and Hygiene, 1991, 45, 65-76.	0.6	161
153	Hepatic granuloma in a man from North America caused by a nymph of Linguatula Serrata. Pathology, 1988, 20, 198-199.	0.3	33
154	Nodules in the Conjunctiva, Bung-Eye, and Bulge-Eye in Africa Caused by Mansonella Perstans. American Journal of Tropical Medicine and Hygiene, 1988, 38, 553-557.	0.6	42
155	South American Brugian Filariasis: Report of a Human Infection Acquired in Peru. American Journal of Tropical Medicine and Hygiene, 1988, 39, 185-188.	0.6	13
156	12 Cercarial dermatitis: The swimmer's itch. Clinics in Dermatology, 1987, 5, 88-91.	0.8	32
157	Adult Mansonella perstans in the Abdominal Cavity in Nine Africans. American Journal of Tropical Medicine and Hygiene, 1987, 37, 578-584.	0.6	13
158	Aids Case for Diagnosis, 1986 Military Medicine. Military Medicine, 1986, 151, M81-M88.	0.4	1
159	8-Aminoquinolines., 0,, 123-151.		9